Novo Nordisk A/S

New York Stock Exchange
Back to all articles
Bullish +65

Novo Nordisk A/S - share repurchase programme - The Manila Times

AI-generated analysis

📈 Novo Nordisk initiated a specific share repurchase programme for B shares on May 6, 2026, with an authorized limit of up to DKK 11.2 billion.

💰 As of August 14, 2026, the company has repurchased 28.9 million B shares totaling DKK 8.08 billion at an average price of DKK 279.80 per share.

🏦 Novo Nordisk currently holds 42.9 million B shares as treasury stock, which accounts for 1.0% of its total share capital.

📅 The broader annual buyback programme runs from February 4, 2026, to February 4, 2027, with a total cap of DKK 15 billion.

🌍 Novo Nordisk operates as a leading global healthcare company with a workforce of approximately 68,800 employees in 80 countries.

📊 The company markets its products in around 170 countries and lists its ADRs on the New York Stock Exchange under the ticker NVO.

Bullish Signals
  • Novo Nordisk is executing a substantial share repurchase programme, having already spent DKK 8.08 billion to buy back nearly 29 million shares as of mid-August 2026.
  • The company's active buyback activity reduces the number of outstanding shares, which can support earnings per share and signal management confidence in the stock's valuation.
  • Novo Nordisk maintains a robust global presence with operations in 80 countries and product distribution in 170 countries, reinforcing its position as a leading healthcare firm.
Full Analysis
Novo Nordisk initiated a share repurchase programme on May 6, 2026, specifically targeting its B shares under the Safe Harbour Rules. The company plans to repurchase up to DKK 11.2 billion in B shares between May 6, 2026, and February 1, 2027, as part of a broader annual authorization of up to DKK 15 billion starting February 4, 2026. As of August 14, 2026, Novo Nordisk has executed significant buybacks, purchasing 28.9 million B shares at an average price of DKK 279.80 per share. These transactions have resulted in a total transaction value of approximately DKK 8.08 billion, contributing to the company's treasury holdings. Following these activities, Novo Nordisk now holds 42.9 million B shares as treasury stock, representing 1.0% of its total share capital. The company's total outstanding A and B shares stand at 4.465 billion units, including the treasury shares, reflecting a strategic move to manage capital structure and potentially support shareholder value. Novo Nordisk remains a leading global healthcare firm founded in 1923 with headquarters in Denmark, employing roughly 68,800 people across 80 countries. Its products are marketed in approximately 170 countries, and its ADRs trade on the New York Stock Exchange under the ticker NVO.